Multiple Myeloma

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

By

MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.

Optimal Management of Myeloma With Bortezomib

Optimal Management of Myeloma With Bortezomib

By

In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

By

Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

By

Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

By

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

BBD Regimen Efficacious as First-line Therapy for Myeloma

BBD Regimen Efficacious as First-line Therapy for Myeloma

By

Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

By

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

By

A pooled analysis confirms the role of upfront autologous HCT as the standard approach for all young patients with multiple myeloma.

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

By

In this study, maintenance therapy with bortezomib plus thalidomide was compared with thalidomide alone or interferon alfa-2b alone in patients with newly diagnosed symptomatic multiple myeloma. Study findings demonstrate an impact on progression-free survival.

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

By

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

By

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

By

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

By

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

By

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Selinexor Plus Low Dose Dex Active in Heavily Pretreated Refractory Myeloma

Selinexor Plus Low Dose Dex Active in Heavily Pretreated Refractory Myeloma

By

Selinexor in combination with low dose dexamethasone is active in heavily pretreated patients with refractory multiple myeloma.

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

By

The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

By

A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

By

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Beta-blockers May Improve Survival in Multiple Myeloma

Beta-blockers May Improve Survival in Multiple Myeloma

By

Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

By

Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

By

The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

By

A panel of International Myeloma Working Group members  presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

By

In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

By

Amgen talks about its collaboration with Janssen Biotech Inc on clinical trials that assess the combination of carfilzomib (Kyprolis) with daratumumab (Darzalex) in patients with multiple myeloma.

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

By

Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.

Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

By

The phase 3 PANORAMA 1 trial previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone. Final overall survival analysis is presented.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Ixazomib + Dexamethasone Active in Relapsed Multiple Myeloma

Ixazomib + Dexamethasone Active in Relapsed Multiple Myeloma

By

The combination of ixazomib and dexamethasone is clinically active and well tolerated in patients with relapsed multiple myeloma not refractory to bortezomib.

Longer Maintenance Therapy Duration May Improve Survival in Myeloma

Longer Maintenance Therapy Duration May Improve Survival in Myeloma

By

A longer duration of lenalidomide maintenance therapy after autologous HSCT may improve progression-free and overall survival in patients with multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs